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Studies exploring the simultaneous influence of several physiological and environmental
factors on domain-specific cognition in late middle-age remain scarce. Therefore, our
objective was to determine the respective contribution of modifiable risk/protective
factors (cognitive reserve and allostatic load) on specific cognitive domains (episodic
memory, executive functions, and attention), taking into account non-modifiable
factors [sex, age, and genetic risk for Alzheimer’s disease (AD)] and AD-related
biomarker amount (amyloid-beta and tau/neuroinflammation) in a healthy late-middle-
aged population. One hundred and one healthy participants (59.4 ± 5 years; 68
women) were evaluated for episodic memory, executive and attentional functioning
via neuropsychological test battery. Cognitive reserve was determined by the National
Adult Reading Test. The allostatic load consisted of measures of lipid metabolism
and sympathetic nervous system functioning. The amyloid-beta level was assessed
using positron emission tomography in all participants, whereas tau/neuroinflammation
positron emission tomography scans and apolipoprotein E genotype were available for
58 participants. Higher cognitive reserve was the main correlate of better cognitive
performance across all domains. Moreover, age was negatively associated with
attentional functioning, whereas sex was a significant predictor for episodic memory,
with women having better performance than men. Finally, our results did not show
clear significant associations between performance over any cognitive domain and
apolipoprotein E genotype and AD biomarkers. This suggests that domain-specific
cognition in late healthy midlife is mainly determined by a combination of modifiable
(cognitive reserve) and non-modifiable factors (sex and age) rather than by AD
biomarkers and genetic risk for AD.
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INTRODUCTION
The constant increase in life expectancy is associated with an
increase in age-related physical and cognitive dysfunctions
(WHO, 2011). Age-related cognitive changes include a
broad spectrum of clinical categories, including cognitively
normal aging, subjective cognitive decline, and mild cognitive
impairment, and dementia stages. It is now clear that age-related
brain changes associated with Alzheimer’s disease (AD) begin
at least as early as in late middle age (Beason-Held et al., 2013;
Jack and Holtzman, 2013; Ritchie et al., 2015; Coupé et al.,
2019). For example, deposits of amyloid-beta (Aβ) and tau
protein, two main biomarkers of AD pathophysiology, are
observed decades before the first clinical signs of cognitive
decline (Jack and Holtzman, 2013).
The presence of these biomarkers does not, however, mean
that people will necessarily develop clinical AD; they are only
indicative of an increased risk for developing the disease
(Dumurgier et al., 2017; Roe et al., 2018). This implies that the
presence of risk factors can potentially be counterbalanced by
protective factors, which may explain the diversity in decline
rates and trajectories of cognitive aging (Nyberg et al., 2012;
Reuter-Lorenz and Park, 2014; Cabeza et al., 2018). Besides Aβ
and tau proteins (Betthauser et al., 2019), several physiological
and psychological environmental protective and risk factors
were proposed to explain this variability (Norton et al., 2014;
Livingston et al., 2017), such as cognitive reserve (Cabeza
et al., 2018; Stern et al., 2018), allostatic load (Karlamangla
et al., 2014), and genetics, particularly with ε4 polymorphism in
apolipoprotein E (APOE) gene (Greenwood et al., 2014).
As current research in cognitive aging shifts to primary
and secondary prevention, it is important to identify predictors
of cognitive performance as early as possible. Late midlife is,
therefore, an interesting time window, sometimes characterized
by first manifestations of AD pathophysiology and subtle
cognitive changes or cognitive complaints. Moreover, several
chronic diseases or lifestyle choices such as hypertension,
diabetes, obesity, sedentary, and smoking habits are related to
subsequent brain pathology and cognitive decline in later life
(Debette et al., 2011; Livingston et al., 2020). In addition, the
factors affecting cognition in late midlife differ from factors that
are important in older age (McFall et al., 2019). Therefore, a
better understanding of risk and protective factors for cognition
in late midlife would provide valuable insight for lifestyle changes
and/or interventions.
Cognitive reserve refers to adaptability (i.e., efficiency,
capacity, and flexibility) of cognitive processes that help
counteract physiological changes associated with brain aging,
pathology, or insult (Stern et al., 2018). Cognitive reserve helps
to maintain normal cognitive performance in the presence of
pathology through the recruitment of alternative brain networks,
altered brain metabolism (Bastin et al., 2012), or alternative
cognitive strategies. The influence of cognitive reserve factors
on cognition in normal aging observed in cross-sectional studies
is grounded on the positive association between cognitive
efficiency, which refers to optimal performance on a cognitive
task (Hoffman and Schraw, 2010), and (a) higher level of
education and intelligence (Fratiglioni and Wang, 2007; Meng
and D’Arcy, 2012; Osone et al., 2015; Bright et al., 2018) for
reviews), (b) employment complexity and autonomy (Bosma
et al., 2003; Ansiau et al., 2005; Baldivia et al., 2008; Then
et al., 2014 for reviews), and (c) physical activity, engagement in
cognitively demanding leisure activities, and/or sustained social
interactions (Wang et al., 2012 for a review). These factors
also seem to influence cognitive decline in longitudinal studies
(Schooler et al., 1999; Bosma et al., 2003; Manly et al., 2003;
Andel et al., 2014; Hughes et al., 2018), but the effects are
more mixed than in cross-sectional designs (see Pettigrew and
Soldan, 2019 for a review and discussion). They also delay
pathological cognitive decline, with a later onset of AD in
individuals with higher reserve (Stern et al., 2018). Importantly,
these cognitive reserve factors may have compensatory effects
already in middle-aged people, as shown for global cognition
and visual abilities (Ferreira et al., 2017) and other cognitive
functions, including episodic memory, executive and attentional
processes, but excluding processing speed (De Frias and Dixon,
2014; Hughes et al., 2018).
In contrast, the strains put on physiology and health
have a negative influence on cognitive aging. Several studies
emphasized a link between cardiovascular functioning and
cognition already in midlife (Dahle et al., 2009; Gupta et al.,
2015; Zeki Al Hazzouri et al., 2017), whereas lipid and glucose
metabolism, inflammation, cortisol level, and sympathetic
nervous system functioning were associated with early cognitive
decline (Karlamangla et al., 2005; Wright et al., 2006; Dahle et al.,
2009; Ownby, 2010; Sartori et al., 2012; Ma et al., 2017; Narbutas
et al., 2019). The allostatic load was proposed as a comprehensive
index gathering the physiological stressors (Karlamangla et al.,
2002) that are negatively associated with episodic memory
performance and executive functioning in middle-aged and older
adults (Karlamangla et al., 2014).
Also, ε4 polymorphism in the APOE gene is an established
genetic risk factor for late-onset AD (Corder et al., 1993).
However, its link with cognitive performance in healthy late
middle-aged individuals remains inconsistent in cross-sectional
studies, with positive, negative, and null associations reported
with cognition, especially for memory performance (for a review,
see Salvato, 2015).
Moreover, there is a broad discussion about the implication
of both pathologic AD proteins (Aβ and tau) in cognitive
performance in late midlife. Whereas some studies found a link
between positron emission tomography (PET) Aβ accumulation
and episodic memory decline in midlife (Hedden et al., 2013;
Schultz et al., 2015; Clark et al., 2016, 2019; Farrell et al., 2017),
other studies did not find any significant relationship (Johnson
et al., 2014; Oh et al., 2014; Song et al., 2015; Mielke et al.,
2016). Furthermore, greater PET Aβ deposition in middle age
was associated with lower vocabulary level (Farrell et al., 2017)
and decreased attentional and executive functioning in some
(Doherty et al., 2015; Clark et al., 2016; Mielke et al., 2016) but
not all studies (Johnson et al., 2014; Hollands et al., 2015; Lim
et al., 2015; Pietrzak et al., 2015; Song et al., 2015). A recent study
combining both Aβ and second-generation tau PET tracers in a
group of late-middle-aged healthy participants demonstrated a
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combined detrimental influence on cognition of both proteins:
participants with both elevated Aβ and tau levels experienced
three times faster cognitive decline in comparison with those
having just one or no elevated biomarkers (Betthauser et al.,
2019). In addition, each biomarker may be associated with
specific aspects of cognition, with tau level associated with verbal
episodic memory and Aβ deposit with executive performance
(Terrera et al., 2020).
Studies exploring the simultaneous influence of several
physiological and psychological risk and protective factors on
cognition in late middle age remain scarce. Our previous cross-
sectional study (Narbutas et al., 2019) in late middle-aged
individuals demonstrated that several categories of modifiable
lifestyle factors, i.e., cognitive reserve and allostatic load,
and particularly some subfactors, i.e., crystallized intelligence,
sympathetic nervous system functioning, and lipid metabolism,
may explain the variability in cognitive performance measured
on a global composite score, which is sensitive to early cognitive
change (Papp et al., 2017). In a similar vein, in a sample
of healthy older adults aged from 53 to 85 years old, stable
memory performance was associated with higher education,
lower depressive symptoms, better living status, normal body
mass index (BMI), normal heart rate, and more social activities,
whereas declining memory performance was associated with
fewer novel cognitive activities, reduced grip strength, abnormal
heart rate, and poorer gait (McFall et al., 2019). Furthermore,
McFall et al. (2019) reported that the association of these factors
with memory status was more marked in the young-old group
(mean age: 64.1 years).
In the continuity of these studies, our objective was
to determine the respective contribution of modifiable
risk/protective factors (allostatic load and cognitive reserve)
on specific cognitive domains (episodic memory, executive
functions, and attention), taking into account non-modifiable
factors (sex, age, and APOE status) and brain AD-related
biomarker level (Aβ and tau) in a healthy late-middle-aged
population with a negative status for AD pathology. When
initiating the study, [18F]THK5351 was a promising tau
radiolabel. However, as detailed in the method section,
[18F]THK5351 was later found to have an important unspecific
binding to the neuroinflammation element (Chiotis et al., 2018).
Although unintended, results with [18F]THK5351 will therefore
reflect a combined burden of tau and neuroinflammation. This
remains of interest as neuroinflammation is gaining increased
attention as a potential mediator of cognitive impairment in
aging (Kumar, 2018). With the present dataset, the authors
predicted that protective factors (higher cognitive reserve
and female sex) would be related to better performance in
domain-specific cognition, whereas adverse factors (worse
allostatic load, older age, APOE ε4 carrier status, higher Aβ,
and tau/neuroinflammation burden) would be related to worse
performance. We further anticipated that the influence of
protective and adverse factors should be visible only for episodic
memory and executive function (Hohman et al., 2017; McFall
et al., 2019; Veldsman et al., 2020). As tau and APOE status were
available only in a subsample of participants, analyses including
these factors will be presented as exploratory.
MATERIALS AND METHODS
Participants
One hundred and one healthy late middle-aged (50–69 years old)
French-speaking community-dwelling men and women (Table 1;
N = 101; 68 women [67.3%]) enrolled in a study designed to
identify biomarkers and lifestyle factors associated with normal
cognitive aging in the context of preclinical dementia [the
Cognitive Fitness in Aging study, see Narbutas et al. (2019)].
No participants reported any recent history of neurological or
psychiatric disease or were taking medication affecting the central
nervous system. All had normal or corrected-to-normal vision
and hearing. Other exclusion criteria were sleep apnea/hypopnea
index ≥ 15/h, assessed during an in-lab night of sleep under
TABLE 1 | Descriptive statistics of demographical data and cognitive outcome
(n = 101).
Mean SD Minimum Maximum
Demographical data
Age, years 59.44 5.29 50.00 69.00
Sex, female, n (%) 68 (67.3%)
Ethnic status, Caucasian, n (%) 101 (100%)
Educational level:
Primary school 0 (0%)
Secondary school 26 (25.7%)
Bachelor degree 37 (36.6%)
Master degree 31 (30.7%)
PhD or higher 7 (6.9%)
Beck Depression Inventory 5.22 4.44 0 17.00
Beck Anxiety Inventory 2.88 3.19 0 17.00
Mattis Dementia Rating Scale 142.53 1.87 134.00 144.00
Cognitive Difficulties Scale 27.89 19.55 0 95.00
Episodic memory score 0 2.17 −8.31 4.40
FCSRT 47.48 6.44 34.00 60.00
Logical memory task, delayed recall 12.13 4.03 2.00 22.00
MST, recognition memory score 0.79 0.15 −0.06 1.00
Executive functioning score 0 3.31 −6.42 8.97
Phonemic Fluency Test, 2 min score 24.66 7.04 7.00 48.00
Semantic Fluency Test, 2 min score 33.82 7.00 20.00 60.00
Digit Span Task, score for inverse order 6.61 2.18 2.00 13.00
TMT*, RT (s) for part B 68.67 20.33 32.00 127.00
N-Back, d′ for 3-back variant 1.18 0.76 −0.26 3.76
SCWT*, interference index 0.10 0.06 −0.02 0.30
Attentional functioning score 0 3.09 −7.35 6.37
DSST, total 2 min score 72.57 12.57 39.00 99.00
TMT*, RT (s) for part A 31.70 8.67 18.00 60.00
N-Back, d′ for 1-back variant 4.70 0.92 1.94 5.76
D2 Test of Attention, GZ-F score 401.73 71.87 185.00 610.00
CRTT*, RT (ms) for non-identical items 694.61 118.88 459.94 1090.31
SD, standard deviation; RT, reaction time; d′, sensitivity index; FCSRT, Free and
Cued Selective Reminding Test (sum of all free immediate recalls + free delayed
recall); MST, Mnemonic Similarity Task; TMT, Trail Making Test; SCWT, Stroop Color
and Word Test; DSST, Digit Symbol Substitution Test; CRTT, Choice Reaction
Time Task (see “Materials and Methods” section for references of tests). ∗Score
inverted for further composite score calculation; thus, higher composite scores
reflect better performance.
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polysomnography, BMI < 18 and > 30 kg/m2, smoking,
illicit drug consumption, excessive consumption of caffeine (>4
cups/day) or alcohol (>14 units/week), diabetes, and shift-work
over the past 6 months. Participants with high levels of depression
and anxiety as assessed by the Beck Depression Inventory
(Beck et al., 1961) and by the 21-item self-rated Beck Anxiety
Inventory (Beck et al., 1988), respectively, were excluded (i.e.,
score > 17), as well as participants with ongoing pharmacological
treatment of depression or anxiety. Participants with treated
(>6 months) hypertension and hypothyroidism were included.
All participants showed normal performance on the Mattis
Dementia Rating Scale (Mattis, 1976) (i.e., score > 130). The
experimental procedures were approved by the local Ethics
Committee of the Faculty of Medicine (University of Liège) and
were in accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involving
humans. All participants gave their signed informed consent
before the experiment, they acknowledge that they cannot be
identified via the paper, were fully anonymized, and received a
financial compensation.
Experimental Design
In this multimodal cross-sectional study, we assessed domain-
specific cognitive performance, i.e., episodic memory and
executive and attentional functioning, as well as cognitive reserve,
allostatic load, and APOE status. We assessed Aβ cortical level
and phosphorylated tau accumulation in regions affected at
Braak stages 1 and 2 of AD using PET. All participants also
underwent quantitative multi-parametric magnetic resonance
imaging (MRI) acquisitions for subsequent preprocessing of PET
data. PET tau protein measurement and APOE status were
available only for 58 participants. All mandatory laboratory
health and safety procedures have been complied with in the
course of conducting the experimental work reported in the
present article.
Neuropsychological Examination
The neuropsychological evaluation consisted of a battery of
cognitive tasks assessing short-term and episodic memory and
attentional and executive functions. The episodic memory
composite score included: Free and Cued Selective Reminding
Test (sum of all free immediate recalls + free delayed recall)
(Grober et al., 2009), Logical Memory Task (delayed recall)
(Wechsler and Stone, 1987), and Mnemonic Similarity Task
(recognition memory score) (Stark et al., 2015). The executive
functioning composite score comprised: Phonemic Fluency Test
(2 min score) and Semantic Fluency Test (2 min score for
an animal category) (Cardebat et al., 1990), Backward Digit
Span Task (total score for inverse order) (Wechsler, 1997), Trail
Making Test (inverted reaction time in seconds for part B) (Bowie
and Harvey, 2006), N-Back Visual Task (d′ for three-back variant)
(Kirchner, 1958), and a computerized version of the Stroop
Color and Word Test (inverted interference index) (Stroop,
1935). The attentional functioning composite score included:
Digit Symbol Substitution Test (total 2 min score) (Wechsler,
1997), Trail Making Test (inverted reaction time in seconds for
part A) (Bowie and Harvey, 2006), N-Back Visual Task (d′ for
one-back variant) (Kirchner, 1958), D2 Test of Attention (GZ-
F score) (Brickenkamp, 1966), and Choice Reaction Time Task
(inverted reaction time in milliseconds for non-identical items)
(Zimmermann and Fimm, 2002). We computed a composite
z-score for each cognitive domain based on the sum of z-scores
on domain-related tasks, with higher scores reflecting better
performance. Neuropsychological evaluation was performed
during two sessions of approximately 75 min, which included
additional neuropsychological tasks that are not considered in the
present analyses.
Cognitive Reserve
A measure of the cognitive reserve was based on previous results
(Narbutas et al., 2019) and consisted of the total score at the
National Adult Reading Test French version (fNART) (Nelson,
1982), also considered as a measure of crystallized intelligence.
The fNART is considered a good proxy of cognitive reserve
(Manly et al., 2003; Starr and Lonie, 2008; Osone et al., 2015).
Allostatic Load
Measures of allostatic load were based on previous methodology
(Narbutas et al., 2019) and consisted of lipid metabolism and
sympathetic nervous system functioning. The lipid metabolism
index was calculated based on measures of BMI, waist–hip
ratio, and blood measures of low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and triglycerides. The
sympathetic nervous system functioning index was calculated
based on the following urinary measures: 24-h excretion of
adrenaline and 24-h excretion of noradrenaline. Both adrenaline
and noradrenaline excretions were also corrected for serum
creatinine level to adjust for lean body mass (Karlamangla et al.,
2014). Final measures of lipid metabolism and sympathetic
nervous system functioning were standardized (i.e., z-scored),
and higher values mean higher allostatic load.
Genotype
APOE genotyping was performed using blood sample DNA
extraction. Common single-nucleotide polymorphisms were
assessed using Infinium OmniExpress-24 BeadChip (Illumina,
San Diego, CA, United States) based on human genome build
hg19 (GRCh37). Genotype imputation was performed using the
“Sanger Imputation Server”1 by choosing Haplotype Reference
Consortium (release 1.1) (Auton et al., 2015) as reference
panel and the pre-phasing algorithm Eagle2 (Loh et al., 2016).
APOE variants were determined by rs7412 and rs429358 single-
nucleotide polymorphisms. Participants were classified into ε4
carries (heterozygous and homozygous) and non-carriers.
Magnetic Resonance Imaging (MRI)
Quantitative multi-parametric MRI acquisition was performed
on a 3-T MR scanner (Siemens MAGNETOM Prisma, Siemens
Healthineers, Erlangen, Germany). Quantitative maps were
obtained by combining images using different parameters
sensitive to distinct tissue properties. Multiparameter mapping
1https://imputation.sanger.ac.uk/
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was based on a multi-echo three-dimensional fast low angle
shot at 1-mm isotropic resolution (Weiskopf and Helms, 2008).
This included three datasets with T1-, proton density-, and
magnetization transfer (MT)-weighted contrasts imposed by
choice of the flip angle (FA = 6◦ for proton density and
MT and 21◦ for T1) and the application of an additional
off-resonance Gaussian-shaped radiofrequency pulse for the
MT-weighted acquisition. MRI multiparameter maps were
processed with the hMRI toolbox2 (Tabelow et al., 2019) and
SPM12 (Welcome Trust Centre for Neuroimaging, London,
United Kingdom) to obtain notably a quantitative MT map
as well as segmented images (gray matter, white matter, and
cerebrospinal fluid), normalized to the standard MNI space using
unified segmentation (Ashburner and Friston, 2005).
Positron Emission Tomography PET
PET acquisition was performed on an ECAT EXACT + HR
scanner (Siemens, Erlangen, Germany) with [18F]Flutemetamol
(N = 97) or [18F]Florbetapir (N = 3) radiotracers to assess Aβ
burden and with [18F]THK-5351 with the intention to measures
tau burden. Although first-generation tau protein radiotracers,
including [18F]THK5351, have been widely studied and proved
to have high affinity and selectivity in vitro (Lemoine et al.,
2017), an important off-binding (∼50%) to monoamine oxidase
B (MAO-B) in vivo, particularly over the basal ganglia (Chiotis
et al., 2018), was reported. A recent comparative analysis of first-
and second-generation radiotracers reported that this off-target
binding might be common to all first-generation radiotracers
and, to a lesser extent, also to second-generation radiotracers
(Murugan et al., 2019). Accordingly, the [18F]THK5351 binding
we measured is a combined marking of phosphorylated tau and
of neuroinflammatory elements such as reactive astrocytes, which
may be triggered in part by tau pathology (Harada et al., 2018).
For all radiotracers, participants received a single dose
of the respective radio-ligands in an antecubital vein (target
dose approximately 185 MBq). Aβ-PET image acquisitions
started 85 min after injection, and four frames of 5 min
were obtained. For [18F]THK-5351-PET, a 10-min transmission
scan was acquired first, and dynamic image acquisitions
started immediately after injection, consisting of 32 frames
(with increasing time duration), with a total duration spent
in the scanner approximately 100 min. All PET images
were reconstructed using a filtered back-projection algorithm,
including corrections for measured attenuation, dead time,
random events, and scatter using standard software.
Average PET images were created using the 4
[18F]Flutemetamol/[18F]Florbetapir frames and using four
frames (40–60 min) for [18F]THK-5351-PET (Lockhart et al.,
2016). Averaged PET images were manually reoriented and
automatically coregistered to the individual space structural
MT map. Flow-field deformation parameters obtained from
DARTEL spatial normalization of MT maps were applied to
averaged coregistered PET images. A standardized uptake value
ratio was calculated using the whole cerebellum as the reference
region for Aβ-PET (Klunk et al., 2015) and cerebellum gray
2http://hmri.info
FIGURE 1 | Parametric [18F]Flutemetamol and [18F]THK5351 uptake. (Top)
panel represents parametric [18F]Flutemetamol binding estimation for subject
having lowest Centiloid value (–8.67 CL) and for subject having highest
Centiloid value (17.79 CL) over a mask covering mostly neocortical regions.
(Bottom) panel represents parametric [18F]THK5351 binding estimation for
subject having lowest SUVR value (1.83 SUVR) and for subject having highest
SUVR value (2.77 SUVR) over a mask covering entorhinal cortex and
hippocampus.
matter for [18F]THK-5351-PET (Ishiki et al., 2018). Volumes of
interests (VOIs) were determined using automated anatomical
labeling atlas, except for brainstem, entorhinal cortex, and
basal ganglia VOIs that were defined with WFU PickAtlas
3.0.5b toolbox on MATLAB 2013a (MathWorks Inc., Natick,
MA, United States). As Aβ-PET images were obtained using
two radiotracers, their standardized uptake value ratio values
were scaled to Centiloid units (CL) (Klunk et al., 2015; Battle
et al., 2018; Navitsky et al., 2018) (for further details, see
Supplementary Material Table 1). Aβ burden was averaged over
a large mask covering neocortical regions (frontal, temporal,
and parietal cortices, insular cortex, precuneus, and anterior
striatum) shown to distinguish AD patients from controls (Klunk
et al., 2015) (see Figure 1). [18F]THK-5351-PET burden (see
Figure 1) was averaged over regions corresponding to Braak
stages 1 and 2 (entorhinal cortex and hippocampus) (Braak and
Braak, 1991; Schöll et al., 2016). Among 100 subjects having
Aβ-PET scans, five subjects were considered as outliers (>3 SD
from the sample mean) and removed before subsequent analyses.
For [18F]THK-5351, one subject was considered as an outlier
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(>3 SD from the sample mean) and excluded from the study
sample (final sample = 58).
Statistical Analyses
We performed statistical analyses with SAS 9.4 for Windows (SAS
Institute, Cary, NC, United States). Generalized linear mixed
models (GLMM; PROC GLIMMIX) were applied to compute
all statistics following the determination of the distribution
of dependent variables using “allfitdist” function on MATLAB
R2013a (MathWorks Inc., Natick, MA, United States). In all
GLMMs, collinearity diagnosis was performed on all predictors
using Tolerance (TOL) and Variance Inflation Factors (VIF) as
criteria. Degrees of freedom were estimated using Kenward–
Roger’s correction. Subject (intercept) effect was included as a
random factor. We defined a p-value < 0.05 as significant.
All models included the composite score from one cognitive
domain (episodic memory, executive functions, and attention) as
the dependent variable and included sex and age as covariates.
At first, GLMMs evaluated the association between each
specific cognitive domain and risk/protective factors (fNART,
sympathetic functioning, and lipid metabolism) in separate
models. Subsequent models included these factors and Aβ burden
on the Centiloid scale. A last exploratory model on a subsample
(N = 58) included the same factors, APOE, and both AD
biomarkers (Aβ, [18F]THK-5351 uptake). Moreover, based on
previous findings showing that the interaction between Aβ and
tau may be even more important for cognitive performance
than their unilateral effect (Hanseeuw et al., 2019), we explored
this type of interaction in models having APOE and both AD
biomarkers (N = 58). Comparison of Bayesian Information
Criterion values for models with and without interactive term for
Aβ and [18F]THK-5351 uptake showed better explanatory power
when interaction effects were not modeled. Consequently, only
models without interaction terms were analyzed. Semi-partial
R2 (Rsp2) was reported for each significant effect as described
previously (Jaeger et al., 2017), provided that degrees of freedom
are estimated using Kenward–Roger’s methods.
For the sake of completeness, we also run these models
with outliers included and using more targeted masks for Aβ
(posterior cingulate cortex and precuneus) (Insel et al., 2020)
and [18F]THK-5351 uptake (entorhinal cortex) (Timmers et al.,
2019). Results did not fundamentally amend those obtained in




Demographics and cognitive outcome are presented in Table 1,
whereas Table 2 gathers raw values of cognitive reserve, allostatic
load, Aβ and tau burden, and APOE.
Episodic Memory
Effect of Cognitive Reserve and Allostatic Load
Assessment of the association between episodic memory and
measures of cognitive reserve and allostatic load showed a
TABLE 2 | Descriptive statistics of raw values of cognitive reserve, allostatic load,
Aβ, tau, and APOE.
Mean SD Minimum Maximum
Cognitive reserve measure (n = 101)
fNART 28.89 4.03 13.00 36.00
Allostatic load measures (n = 101)
Lipid metabolism
Body mass index, kg/m2 24.62 2.88 17.85 30.12
Waist-hips ratio, cm/cm 1.11 0.15 0.72 1.49
LDL, mg/dl 138.15 37.12 45.00 272.00
HDL, mg/dl (higher is better) 65.31 17.84 28.00 149.00
Triglycerides, mg/dl 109.62 55.35 29.00 339.20
Sympathetic nervous system functioning
Urine adrenaline, µg/24 h 8.29 4.56 2.18 25.47
Urine noradrenaline, µg/24 h 37.49 16.23 6.94 95.89
Aβ (n = 95)
CL, centiloid brain mask 0.31 4.57 −8.67 17.79
THK5351 uptake (n = 58)
SUVR, Braak 1 and 2 mask 2.27 0.21 1.83 2.77
APOE (n = 58)
APOE ε4 carriers 10 (17.2%)
APOE ε4 non-carriers 48 (82.8%)
SD, standard deviation; fNART, National Adult Reading Test French version; LDL,
fasting blood low-density lipoprotein cholesterol; HDL, fasting blood high-density
lipoprotein cholesterol; APOE, apolipoprotein E; Aβ, amyloid-beta; CL, Centiloid
units; SUVR, standardized uptake value ratio (see “Materials and Methods” section
for the references of tests and questionnaires).
significant positive association with the score of the fNART
(Table 3A and Figure 2A). Scores of allostatic load were, however,
not associated with episodic memory performance. Moreover,
sex was also significantly associated with episodic memory, with
better performance for women (Figure 2B).
Simultaneous Effect of Modifiable and
Non-modifiable Factors
Subsequent models included the modifiable factors of cognitive
reserve and allostatic load together with non-modifiable factors
(Aβ in a first model, N = 95; tau and APOE in a second
model, N = 58). No association between memory performance
and Aβ burden was detected beyond its association with fNART
values (Table 3B). Similarly, no associations between memory
performance and tau burden and APOE genotype were detected
in the last model (Table 3C).
Finally, we tentatively ran models including outliers and using
other brain region masks for early Aβ/THK5351 uptake. The only
observed change is that the positive association observed with the
score of the fNART now remains significant (see Appendix Tables
A1, B1, respectively, in Supplementary Material Table 2).
Executive Functions
Effect of Cognitive Reserve and Allostatic Load
Executive functioning was significantly and positively associated
with fNART values (Table 4A and Figure 3A), but it was not the
case for measures of allostatic load (Table 4A).
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TABLE 3 | Statistical outcome of GLMM examining associations between episodic
memory (dependent variable) and: (A) scores of cognitive reserve and allostatic
load (n = 101); (B) scores of cognitive reserve and allostatic load, and Aβ (n = 95);
(C) scores of cognitive reserve and allostatic load, Aβ, tau, and APOE (n = 58).
Model A (n = 101) Estimate ± SE F-value (df) P
Sex* −0.47 ± 0.21 5.05 (1,95) 0.03 (Rsp2 = 0.05)
Age −0.03 ± 0.10 0.12 (1,95) 0.73
fNART 0.31 ± 0.10 10.73 (1,95) 0.002 (Rsp2 = 0.10)
Lipid metabolism −0.06 ± 0.10 0.39 (1,95) 0.53
Sympathetic functioning −0.11 ± 0.09 1.32 (1,95) 0.25
Model B (n = 95)
Sex* −0.40 ± 0.22 3.29 (1,88) 0.07
Age −0.001 ± 0.10 0.0 (1,88) 0.99
fNART 0.30 ± 0.10 8.92 (1,88) 0.004 (Rsp2 = 0.09)
Lipid metabolism −0.07 ± 0.10 0.47 (1,88) 0.50
Sympathetic functioning −0.10 ± 0.10 0.88 (1,88) 0.35
Aβ −0.02 ± 0.10 0.05 (1,88) 0.82
Model C (n = 58)
Sex* −0.04 ± 0.30 0.02 (1,49) 0.89
Age −0.20 ± 0.14 2.12 (1,49) 0.15
fNART 0.24 ± 0.15 2.79 (1,49) 0.10
Lipid metabolism 0.04 ± 0.14 0.08 (1,49) 0.78
Sympathetic functioning −0.09 ± 0.15 0.34 (1,49) 0.56
Aβ −0.08 ± 0.15 0.25 (1,49) 0.62
THK5351 uptake −0.01 ± 0.14 0.01 (1,49) 0.93
APOE 0.13 ± 0.36 0.14 (1,49) 0.71
SE, standard error; df, degrees of freedom; Rsp2, Semi-partial R2; fNART, National
Adult Reading Test (French version); Aβ, amyloid-beta; APOE, apolipoprotein E.
*Sex: 1 = male; 2 = female.
Simultaneous Effect of Modifiable and
Non-modifiable Factors
Subsequent models included the modifiable factors of cognitive
reserve and allostatic load together with non-modifiable factors
(Aβ in a first model, N = 95; tau and APOE in a second
model, N = 58). Similarly to episodic memory, no association
between Aβ burden and executive performance was detected
beyond its association with fNART values (Table 4B). In contrast,
there was a significant positive association between executive
functioning and tau burden (Table 4C and Figure 3B), whereas
the association was not significant with the APOE genotype.
When tentatively running models including outliers and
using other brain region masks for early Aβ/THK5351 uptake,
the association was not significant anymore with these masks
(see Appendix Tables A2, B2, respectively, in Supplementary
Material Table 2).
Attentional Functions
Effect of Cognitive Reserve and Allostatic Load
Similar to the other cognitive domains, attentional functioning
was significantly and positively associated with fNART values
but not with measures of allostatic load (Table 5A and
Figure 4A). Moreover, age was significantly negatively associated
with attentional functions (Figure 4B).
Simultaneous Effect of Modifiable and Non-mdifiable
Factors
When including modifiable factors together with non-modifiable
factors (Aβ in a first model, N = 95; tau and APOE in a second
model, N = 58), attentional functioning was not significantly
associated with Aβ burden beyond its association with fNART
values (Table 5B). As for memory performance, an attentional
function also was not significantly associated with tau burden or
APOE genotype (Table 5C).
There were no changes in the associations observed with the
exploratory models, including outliers and using other brain
region masks for early Aβ/THK5351 uptake (see Appendix Tables
A3, B3, respectively, in Supplementary Material Table 2).
DISCUSSION
This study investigated whether performance assessed over
episodic memory, executive and attentional domains in healthy
late-middle-aged individuals is associated with a combination
of risk/protective factors (crystallized intelligence, sympathetic
FIGURE 2 | (A) Scatter plot displaying association between episodic memory and fNART (N = 101). Regression was used for visual display only and not as a
substitute for full GLMM statistics. (B) Box plot visualizing episodic memory score according to sex (N = 101).
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TABLE 4 | Statistical outcome of GLMM examining associations between
executive functions (dependent variable) and: (A) scores of cognitive reserve and
allostatic load (n = 101); (B) scores of cognitive reserve and allostatic load, and Aβ
(n = 95); (C) scores of cognitive reserve and allostatic load, Aβ, tau, and APOE
(n = 58).
Model A (n = 101) Estimate ± SE F-value (df) P
Sex* 0.06 ± 0.20 0.10 (1,95) 0.75
Age −0.17 ± 0.09 3.30 (1,95) 0.07
fNART 0.46 ± 0.09 25.49 (1,95) <0.0001 (Rsp2 = 0.21)
Lipid metabolism 0.07 ± 0.09 0.60 (1,95) 0.44
Sympathetic
functioning
0.12 ± 0.09 1.89 (1,95) 0.17
Model B (n = 95)
Sex* 0.04 ± 0.21 0.05 (1,88) 0.83
Age −0.17 ± 0.10 2.96 (1,88) 0.09
fNART 0.47 ± 0.10 23.73 (1,88) <0.0001 (Rsp2 = 0.21)
Lipid metabolism 0.07 ± 0.10 0.59 (1,88) 0.45
Sympathetic
functioning
0.13 ± 0.09 1.86 (1,88) 0.18
Aβ 0.05 ± 0.10 0.24 (1,88) 0.63
Model C (n = 58)
Sex* −0.17 ± 0.25 0.46 (1,49) 0.50
Age −0.13 ± 0.12 1.28 (1,49) 0.26
fNART 0.59 ± 0.12 23.09 (1,49) <0.0001 (Rsp2 = 0.32)
Lipid metabolism −0.02 ± 0.12 0.02 (1,49) 0.89
Sympathetic
functioning
0.06 ± 0.13 0.25 (1,49) 0.62
Aβ 0.12 ± 0.13 0.91 (1,49) 0.35
THK5351 uptake 0.25 ± 0.12 4.49 (1,49) 0.04 (Rsp2 =.080.08)
APOE 0.46 ± 0.31 2.24 (1,49) 0.14
SE, standard error; df, degrees of freedom; Rsp2, semi-partial R2; fNART, National
Adult Reading Test (French version); Aβ, amyloid-beta; APOE, apolipoprotein E.
∗Sex: 1 = male; 2 = female.
functioning and lipid metabolism, sex, age, and APOE status)
as well as with levels of AD-related brain biomarkers (Aβ and
THK5351 uptake). Our main finding is that higher crystallized
intelligence, a robust proxy of cognitive reserve (Manly et al.,
2003; Starr and Lonie, 2008; Osone et al., 2015), is the main
correlate of better cognitive performance across all domains. Our
results further indicated that age was negatively associated with
attentional functioning but not with other cognitive domains,
whereas we also detected a significant effect of sex on episodic
memory, with women having better performance than men.
Finally, our results did not reveal significant associations between
performance over any cognitive domain and APOE genotype
or AD biomarkers, except for an unanticipated positive link
between [18F]THK5351 binding over Braak 1 and 2 stage regions
and executive performance, which may be specific to the brain
region considered.
Modifiable Factors (Cognitive Reserve
and Allostatic Load)
A positive influence of specific aspects of cognitive reserve
on cognition was previously reported in older individuals
(Ansiau et al., 2005; Bright et al., 2018; Falck et al., 2018;
Ihle et al., 2018), as well as in late midlife (Narbutas et al.,
2019). We provide evidence that cognitive reserve (assessed
by crystallized intelligence) is positively associated with
performance across all three domain-specific cognition with
important effect sizes (semi-partial R2 ranging from 0.09 to
0.32 depending on cognitive domain and covariates included
in the models). Crystallized intelligence has been shown to
be an even better predictor of cognitive efficiency in aging
than education (Manly et al., 2003; Osone et al., 2015), and
the current study clearly points out the predictive value
of crystallized intelligence for cognitive efficiency in late-
middle-aged population devoid of significant AD pathology.
Nevertheless, the associations between specific cognitive
domains and the measure of cognitive reserve (fNART)
we observed here may simply mean that fluid intelligence
matches quite well with crystallized intelligence in that
type of population.
In addition to a significant positive link between cognitive
reserve and domain-specific cognition, we also demonstrate
that this link remains unaffected by the inclusion of Aβ
burden PET marker for executive and attentional functioning,
and our results further support that it is also the case for
FIGURE 3 | (A) Scatter plot displaying association between executive functioning and fNART (N = 101). (B) Scatter plot displaying association between executive
functioning and tau level in Braak regions 1 and 2 (N = 58). Regressions were used for visual display only and not as a substitute for full GLMM statistics.
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FIGURE 4 | Scatter plots visualizing association between attentional functioning, fNART (A), and age (B) (N = 101). Regressions were used for visual display only
and not as a substitute for full GLMM statistics.
TABLE 5 | Statistical outcome of GLMM examining associations between
attentional functioning (dependent variable) and: (A) scores of cognitive reserve
and allostatic load (n = 101); (B) scores of cognitive reserve and allostatic load,
and Aβ (n = 95); (C) scores of cognitive reserve and allostatic load, Aβ, tau, and
APOE (n = 58).
Model A (n = 101) Estimate ± SE F-value (df) P
Sex* 0.006 ± 0.20 0.0 (1,95) 0.98
Age −0.26 ± 0.09 7.78 (1,95) 0.006 (Rsp2 = 0.08)
fNART 0.37 ± 0.09 16.15 (1,95) 0.0001 (Rsp2 = 0.15)
Lipid metabolism 0.02 ± 0.09 0.06 (1,95) 0.81
Sympathetic
functioning
0.16 ± 0.09 3.00 (1,95) 0.09
Model B (n = 95)
Sex* −0.05 ± 0.21 0.05 (1,88) 0.82
Age −0.22 ± 0.10 5.18 (1,88) 0.03 (Rsp2 ( 0.06)
fNART 350.35 ± 0.10 13.12 (1,88) 0.0005 (Rsp2 = 0.13)
Lipid metabolism 0.04 ± 0.10 0.21 (1,88) 0.65
Sympathetic
functioning
0.18 ± 0.10 3.74 (1,88) 0.06
Aβ −0.07 ± 0.10 0.47 (1,88) 0.49
Model C (n = 58)
Sex* 0.002 ± 0.27 0.0 (1,49) 0.995
Age −0.19 ± 0.13 2.15 (1,49) 0.15
fNART 0.42 ± 0.13 9.87 (1,49) 0.003 (Rsp2 = 0.19)
Lipid metabolism 0.01 ± 0.13 0.01 (1,49) 0.91
Sympathetic
functioning
0.19 ± 0.14 1.86 (1,49) 0.18
Aβ −0.04 ± 0.14 0.07 (1,49) 0.79
THK5351 uptake 0.08 ± 0.13 0.41 (1,49) 0.52
APOE 0.12 ± 0.34 0.12 (1,49) 0.73
SE, standard error; df, degrees of freedom; Rsp2, semi-partial R2; fNART, National
Adult Reading Test (French version); Aβ, amyloid-beta; APOE, apolipoprotein E.
∗Sex: 1 = male; 2 = female.
APOE and tau/neuroinflammation status, although based on
a subsample only.
Surprisingly, sympathetic functioning and lipid metabolism,
two specific measures of allostatic load, were not related to
domain-specific cognition in our sample. This is in contrast
to previous studies showing that higher allostatic load, a
comprehensive index of physiological load related to stress, is
related to worse global cognitive performance in late midlife
(Narbutas et al., 2019) and both episodic memory and executive
functioning in middle-aged and older adults (Karlamangla
et al., 2014). It may be that the effect of the allostatic load
has a more important manifestation on cognition when the
cognitive status is measured using tools sensitive to early
cognitive decline (Narbutas et al., 2019). In fact, cognitive
composites assessing cognitive status over several specific
cognitive domains were proposed as an efficient tool to track
the earliest cognitive change (Rentz et al., 2013; Papp et al.,
2017).
To sum up, our results are only partially in line with previous
findings showing an important effect of modifiable factors
promoting late-life cognition, including higher educational level,
treatment of cardiovascular diseases, diet, calorie restriction,
and exercise, or more generally allostatic load (Karlamangla
et al., 2014; Norton et al., 2014; Livingston et al., 2017;
Bhatti et al., 2020). We observed an expected positive
influence of cognitive reserve by its proxy of crystallized
intelligence but no effect of health-related factors. A possible
explanation is that the effect of health-related factors on
specific cognitive processes could be mediated by other
factors not investigated here, such as changes in brain
structure and function (Booth et al., 2015; Neth et al.,
2020).
Non-modifiable Factors (Sex, Age, and
Apolipoprotein EAPOE)
We detected a significant effect of sex for episodic memory,
with women having better performance than men, but only
without controlling for AD biomarker status and APOE, which
may imply that AD biomarker and APOE are explaining a
small and non-significant portion of the variance that allows
for sex to emerge as significant. Sex was reported to be
an important predictor for stable memory in aging and for
cognitive efficiency in late midlife, with women showing less
decline on a combined score using four recall measures
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from two standard episodic memory tasks (McFall et al.,
2019) and better performance on the Preclinical Alzheimer
Cognitive Composite score (PACC5), a composite measure
known to be sensitive to early subtle cognitive changes,
possibly leading to dementia (Narbutas et al., 2019). Sex
differences were also observed in specific cognitive domains
such as episodic memory, executive and attentional functioning,
and language in older participants (mean age = 67 years)
(McCarrey et al., 2016). It also seems that women have a
greater number of factors predicting memory resilience than
men (McDermott et al., 2017). For example, a sex difference
in cognitive performance may be explained by hormonal
differences (Koyama et al., 2016), genetic factors, differences
in brain networks, socioeconomic roles, and health choices
(Deckers et al., 2018).
We further found that older age was related to worse
attentional functioning. This link may be explained by the
dependence of general attentional functions, including working
memory, on processing speed (Mella et al., 2015), at least
for our composite score of attention, which required lots of
resources for visual stimuli detection and fast manual responses.
Indeed, processing speed is known as the cognitive function,
which is affected early in life (i.e., from the third decade)
and undergoes a stable decline in cognitive aging (Eckert
et al., 2010). In contrast, we did not detect a significant
age effect for the executive and memory domains. A recent
study that identified modifiable risk factors for episodic
memory maintenance and/or decline in healthy individuals
also revealed that the influence of those factors differed
according to age strata (55–72.4 vs. 72.5–95 years) (McFall
et al., 2019). However, age itself was not a robust predictor
for memory maintenance or decline in that study. In our
sample with a relatively narrow age range (50–69 years),
crystallized intelligence seems, therefore, to be associated more
strongly with performance in episodic memory and executive
functions than age.
Finally, we found that APOE status had no significant impact
on domain-specific cognition, which is in line with previous
data focusing on episodic memory (Salvato, 2015) and working
memory (Greenwood et al., 2014).
Alzheimer’s Disease AD Biomarkers
Aβ level was not related to domain-specific cognitive measures
both when assessing the effect of Aβ alone or when also
including THK5153 uptake in a subsample of participants.
A similar picture emerges for our exploration of the association
between domain-specific cognitive performance and THK5251
uptake except for a surprising positive association with
executive performance. The latter results contrast with the
scarce previous studies that quite consistently reported that
higher global or large neocortical regional tau level was mostly
related to worse episodic memory performance, such as list
learning, which predominantly relies on the hippocampus
(Aschenbrenner et al., 2018; Ossenkoppele et al., 2019; Terrera
et al., 2020).
Our surprising finding may arise from the unspecific
binding of THK5351 to MAO-B in reactive astrocytes
(Lemoine et al., 2017). Neuroinflammation processes involve
the activation of glial cells (microglia and astrocytes) and
the release of inflammatory mediators (cytokines) (López-
Valdés and Martínez-Coria, 2016). The initial function of
neuroinflammation is to protect the central nervous system
from pathogens by isolating damaged tissue from uninjured
areas and cleaning and repairing the extracellular matrix.
In contrast, chronic inflammation leads to the degradation
of neural tissue and of the blood–brain barrier. Moreover,
during normal aging, glial cells become more reactive, which
may exacerbate cytokine response and subsequent cognitive
decline (Godbout and Johnson, 2009). Neuroinflammation
may, in fact, drive part of AD pathology independently
of Aβ accumulation (Cunningham et al., 2009; Heppner
et al., 2015; López-Valdés and Martínez-Coria, 2016). The
link between neuroinflammation and cognition was rarely
assessed over specific cognitive domains. Because of the mixed
binding of THK5351 to tau and MAO-B, our results do
not provide, however, clear insights about this question, but
they warrant future research using in vivo markers specific
to neuroinflammation, such as [11C]PK11195 PET ligand
(Kreisl et al., 2020).
The unanticipated link between THK5351 uptake and
executive performance may also be due to the binding of
the marker to actual tau aggregates. Early tau accumulation
begins in the entorhinal cortex and hippocampus (Braak and
Braak, 1991) and brainstem nuclei such as the dorsal raphe
and locus coeruleus (Uematsu et al., 2018). Therefore, one
could speculate that a link between better executive performance
and higher tau accumulation in the entorhinal cortex and
hippocampus may be explained by compensatory mechanisms
in the brain networks encompassing executive functions (e.g.,
prefrontal cortex), which are activated when tau level increases
in the medial temporal lobe (MTL). There is indeed evidence
of functional connectivity between the prefrontal cortex and
MTL through thalamic pathways (Ketz et al., 2015), and
fiber bundles connecting the prefrontal cortex and MTL were
reported both in monkeys and humans (Folloni et al., 2019).
However, as this link is no more significant when more targeted
masks are used in the analyses (see Appendix Table C2), the
results require replication, and their interpretation shall be
considered tentative.
This raises the question of the brain region considered when
assessing the link between AD PET biomarkers and behavior.
For Aβ, we have used a VOI covering most neocortical regions
and the anterior striatum, as it was reported to be a sensitive
mask to distinguish between AD patients and controls (Klunk
et al., 2015). For THK5351 uptake, the VOI encompassed
Braak stages 1 and 2 regions, which are undergoing initial
tauopathy (entorhinal cortex and hippocampus) (Schöll et al.,
2016). Smaller VOIs including only regions implicated in
specific cognitive domains may be more precise in isolating a
link with specific cognitive domains. Indeed, recent evidence
prompts that each biomarker is associated with a specific
cognitive function that has its regional neural correlates, with
a primarily hippocampal task (e.g., verbal episodic memory)
being associated with higher levels of tau and a frontal
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executive task (e.g., coding) related to higher levels of amyloid
(Terrera et al., 2020). However, results of other previous
studies are mixed: Aβ was sometimes related to episodic
memory performance, and more consistently so in longitudinal
studies (Hedden et al., 2013; Schultz et al., 2015; Clark et al.,
2016, 2019; Farrell et al., 2017), but not always (Johnson
et al., 2014; Oh et al., 2014; Song et al., 2015; Mielke
et al., 2016), whereas a link with executive functions was
demonstrated only in a few studies (Doherty et al., 2015;
Clark et al., 2016; Mielke et al., 2016), in contrast to a
majority of studies that did not find any significant link
(Johnson et al., 2014; Hollands et al., 2015; Lim et al., 2015;
Pietrzak et al., 2015; Song et al., 2015). In addition to VOI,
inconsistencies could also be due to differences in the number
of amyloid deposits across cohorts, with only studies including
participants with the higher level of Aβ or tau pathology (i.e.,
Aβ/tau positive patients) showing a significant amyloid/tau-
cognition association.
Limitations
Beyond the choice of the region of interest, other methodological
choices may have impacted our results. First, we selected
volunteers devoid of many health and lifestyle factors
(Baumgart et al., 2015; Kane et al., 2017; Livingston et al.,
2017) that typically increase the risk for pathological
cognitive decline (e.g., no smoking, limited caffeine and
alcohol intake, relatively low body mass index, no current
treatment for psychiatric disorders, etc.). This may decrease
the variability in certain factors, especially concerning
allostatic load measures. However, our selection bias
allows assessing associations with cognition away from
these risk factors.
Moreover, the lack of associations between AD biomarker
and cognition may also be due to a low level of AD
biomarkers. Indeed, all our participants had a negative biomarker
status for AD pathology. Previous studies usually showed that
when Aβ levels are low, the magnitude of the link between
amyloid and cognition is small (Farrell et al., 2018; Leal
et al., 2018). Consequently, a very large sample would be
needed for identifying such effects in a cross-sectional study.
The longitudinal follow-up of our participants should help to
determine if the presence of sub-clinical level of AD biomarkers
is associated with subsequent cognitive decline.
Finally, we could consider that our study had the potentially
limited power for evaluating multiple risk and protective factors
simultaneously, given the sample size and extensive phenotyping
of our 101 participants.
Conclusion
Our results show that domain-specific cognition in normal
aging is determined by a combination of modifiable and non-
modifiable factors, with a better cognitive reserve and, more
precisely, crystallized intelligence being the best predictor for
performance in all cognitive domains, as well as sex for
episodic memory and age for attention. In addition, our cross-
sectional study showed that domain-specific cognition was
mostly unrelated to APOE genotype and AD biomarkers in the
healthy late-middle-aged population. Future longitudinal studies
focusing on the same population are required to assess further
associations between domain-specific cognitive decline, PET, and
genetic markers.
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